{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:30:23Z","timestamp":1771007423130,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.cld.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T10:17:09Z","timestamp":1364379429000},"page":"229-242","source":"Crossref","is-referenced-by-count":23,"title":["Primary Biliary Cirrhosis"],"prefix":"10.1016","volume":"17","author":[{"given":"Frank","family":"Czul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.cld.2012.12.003_bib1","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3748\/wjg.14.3313","article-title":"Clinical features and management of primary biliary cirrhosis","volume":"14","author":"Crosignani","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.mcg.0000225653.07932.8f","article-title":"Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy","volume":"41","author":"Lazaridis","year":"2007","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-0676.1995.tb00110.x","article-title":"Prediction of prognosis of primary biliary cirrhosis in Japan","volume":"15","author":"Inoue","year":"1995","journal-title":"Liver"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.510270303","article-title":"Characterization of antimitochondrial antibodies in health adults","volume":"27","author":"Mattalia","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-2008-1040501","article-title":"Heterogeneity of antimitochondrial antibodies","volume":"9","author":"Berg","year":"1989","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0676.1995.tb00687.x","article-title":"Mitochondrial antigen\/antibody systems in primary biliary cirrhosis: revisited","volume":"15","author":"Berg","year":"1995","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","article-title":"Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis","volume":"34","author":"Invernizzi","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cld.2008.02.009","article-title":"Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value","volume":"12","author":"Muratori","year":"2008","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis","volume":"25","author":"Invernizzi","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.510260103","article-title":"Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation","volume":"26","author":"Kim","year":"1997","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2012.12.003_bib18","first-page":"106","article-title":"Primary biliary cirrhosis: diagnosis, pathology and pathogenesis","volume":"59","author":"Scheuer","year":"1983","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/he.2000.5984","article-title":"Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines","volume":"31","author":"Heathcote","year":"2000","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.cld.2012.12.003_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMct074694","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis","volume":"357","author":"Lindor","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/CS20110184","article-title":"Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications","volume":"121","author":"Roma","year":"2011","journal-title":"Clin Sci (Lond)"},{"issue":"9","key":"10.1016\/j.cld.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.cdd.4400560","article-title":"Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation","volume":"6","author":"Rodrigues","year":"1999","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/hep.510250423","article-title":"Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells","volume":"25","author":"Bergamini","year":"1997","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/0016-5085(90)91091-J","article-title":"Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study","volume":"98","author":"Balasubramaniam","year":"1990","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000551.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gong","year":"2008","journal-title":"Cochrane Database\u00a0Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2012.12.003_bib31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.cld.2012.12.003_bib32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/jhep.2001.20894","article-title":"Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center","volume":"33","author":"Liermann Garcia","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2012.12.003_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-230X-10-144","article-title":"Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008","volume":"10","author":"Kuiper","year":"2010","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2012.12.003_bib38","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib39","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hep.22831","article-title":"Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol","volume":"50","author":"Kaplan","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2012.12.003_bib42","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/j.1572-0241.2001.05270.x","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?","volume":"96","author":"Angulo","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2012.12.003_bib43","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2012.12.003_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004385.pub3","article-title":"Methotrexate for primary biliary cirrhosis","author":"Giljaca","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004789.pub2","article-title":"Colchicine for primary biliary cirrhosis","author":"Gong","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.cld.2012.12.003_bib46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2011.05.010","article-title":"Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis","volume":"9","author":"Leung","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib47","article-title":"Azathioprine for primary biliary cirrhosis","author":"Gong","year":"2007","journal-title":"Cochrane\u00a0Database Syst Rev"},{"issue":"13","key":"10.1016\/j.cld.2012.12.003_bib48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/j.1875-9114.1997.tb03082.x","article-title":"Mycophenolate mofetil","volume":"17","author":"Sievers","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib53","first-page":"168","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.trsl.2009.09.009","article-title":"Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial","volume":"155","author":"Askari","year":"2010","journal-title":"Transl Res"},{"issue":"Suppl 6","key":"10.1016\/j.cld.2012.12.003_bib55","first-page":"VI1","article-title":"Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology","volume":"45","author":"Devlin","year":"1999","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cld.2011.08.008","article-title":"Recurrent and de novo autoimmune liver diseases","volume":"15","author":"Mendes","year":"2011","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-0012.2005.00471.x","article-title":"Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients","volume":"20","author":"Jacob","year":"2006","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.cld.2012.12.003_bib58","first-page":"35","article-title":"Mayo risk score for primary biliary cirrhosis: a useful tool for the prediction of course after liver transplantation?","volume":"13","author":"Jacob","year":"2008","journal-title":"Ann Transplant"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib59","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S1089-3261(03)00099-0","article-title":"Liver transplantation for primary biliary cirrhosis","volume":"7","author":"MacQuillan","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1568-9972(02)00103-9","article-title":"Liver transplantation for primary biliary cirrhosis","volume":"2","author":"Neuberger","year":"2003","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib61","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2012.12.003_bib62","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","article-title":"Fibrate for treatment of primary biliary cirrhosis","volume":"37","author":"Iwasaki","year":"2007","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.cld.2012.12.003_bib63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.cld.2012.12.003_bib64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2012.12.003_bib66","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","author":"Honda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2012.12.003_bib67","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(10)60004-9","article-title":"2 Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? an international study evaluating the addition of INT-747 to ursodeoxycholic\u00a0acid","volume":"52","author":"Mason","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2012.12.003_bib68","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1572-0241.2004.40741.x","article-title":"Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis","volume":"99","author":"Mason","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2012.12.003_bib69","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1365-2036.2008.03799.x","article-title":"Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol","volume":"28","author":"Mason","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"S1","key":"10.1016\/j.cld.2012.12.003_bib70","first-page":"532A","article-title":"Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA)","volume":"46","author":"Myers","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2012.12.003_bib71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib72","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaut.2007.10.003","article-title":"Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis","volume":"30","author":"Allina","year":"2008","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.cld.2012.12.003_bib73","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaut.2006.11.004","article-title":"T\u00a0cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis","volume":"27","author":"Allina","year":"2006","journal-title":"J\u00a0Autoimmun"},{"issue":"S1","key":"10.1016\/j.cld.2012.12.003_bib74","first-page":"706A","article-title":"High dose vitamin D3 treatment enhances macrophage phagocytosis of apoptotic cells and lowers bilirubin levels in PBC","volume":"48","author":"Allina","year":"2008","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2012.12.003_bib75","first-page":"1137A","article-title":"Is biochemical response to ursodeoxycholic acid therapy impacted by vitamin D plasma level in patients with primary biliary cirrhosis?","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326112001493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326112001493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:24:16Z","timestamp":1715131456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326112001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1089326112001493"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2012.12.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}